Mounach Aziza, El Maghraoui Abdellah
Rheumatology Department, Military Hospital Mohammed V, Rabat, Morocco.
Open Access Rheumatol. 2014 Aug 13;6:83-90. doi: 10.2147/OARRR.S44550. eCollection 2014.
Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially affects the sacroiliac joints and the tip of the column, with a tendency to later ankylosis. Peripheral joints, enthesis, and other extra-articular involvement may be observed. Tumor necrosis factor (TNF) inhibitors are now well-established, effective drugs in the treatment of AS symptoms. Adalimumab, which is a fully human monoclonal antibody that binds to and neutralizes TNF, has demonstrated efficacy in treating AS symptoms, including axial involvement, peripheral arthritis, enthesitis, uveitis, gut involvement, and psoriasis. Furthermore, adalimumab has showed an overall acceptable safety profile. In this paper, we review the efficacy and safety profile of adalimumab in the treatment of AS, and discuss its differences from the other anti-TNF drugs reported in the literature.
强直性脊柱炎（AS）是脊柱关节炎最常见且最严重的亚型。它也可能是其他脊柱关节炎亚型发展的结果。AS 优先累及骶髂关节和脊柱末端，有后期发生关节强直的倾向。也可观察到外周关节、附着点及其他关节外受累情况。肿瘤坏死因子（TNF）抑制剂目前是治疗 AS 症状的成熟有效药物。阿达木单抗是一种全人源单克隆抗体，可结合并中和 TNF，已证明其在治疗 AS 症状方面有效，包括中轴受累、外周关节炎、附着点炎、葡萄膜炎、肠道受累及银屑病。此外，阿达木单抗总体安全性良好。在本文中，我们综述了阿达木单抗治疗 AS 的疗效和安全性，并讨论其与文献中报道的其他抗 TNF 药物的差异。
